<DOC>
	<DOC>NCT01198002</DOC>
	<brief_summary>The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate. This study is comprised of 3 periods: Period 1 - 52 week blinded treatment Period 2 - additional 48 week unblinded treatment Period 3 - 48 week post treatment follow up</brief_summary>
	<brief_title>A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years Regular use of methotrexate (MTX) in the past 12 weeks, with the dose being stable during the past 8 weeks At least 8 tender and swollen joints At least one erosion of a hand or foot joint observed on an Xray An abnormally high Creactive protein (CRP) level or erythrocyte sedimentation rate (ESR) Positive for Rheumatoid Factor (RF) or Anticyclic citrullinated peptide (CCP) antibody Woman must not be pregnant, breastfeeding, or become pregnant during the study Use of unstable doses of nonsteroidal inflammatory drugs (NSAIDS) in the past 6 weeks Steroid injection or intravenous (iv) infusion in the last 6 weeks Use of more than 10 mg/day of oral steroids in the last 6 weeks History of an inadequate response to a biologic diseasemodifying antirheumatic drug (DMARD) History of a serious reaction to other biological DMARDs History of the use of rituximab or other B cell therapy Use of DMARDS other than MTX, hydroxychloroquine, or sulfasalazine within the last 8 weeks Use of leflunomide within the last 12 weeks (unless cholestyramine was used to speed up the elimination of leflunomide) Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasalspray flu vaccines) Hepatitis or HIV A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months Symptoms of herpes zoster or herpes simplex within the last month Active or latent tuberculosis (TB) Current symptoms of a serious disorder or illness Use of an investigational drug within the last month History of the use of rituximab, any other B cell targeted biotherapy, or denosumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>